购物车
- 全部删除
- 您的购物车当前为空
AGI-026(AGI-12026)是一种新型和有效的突变体异柠檬酸脱氢酶mIDH1/2双重抑制剂,具有口服和穿透血脑屏障的优点,脑组织中的药物浓度与血浆浓度的比值(脑/血浆比)达到 1.5,能够减少致癌代谢物 d-2-羟基戊二酸(2-HG) 的积累,用于研究mIDH胶质瘤。
为众多的药物研发团队赋能,
让新药发现更简单!
AGI-026(AGI-12026)是一种新型和有效的突变体异柠檬酸脱氢酶mIDH1/2双重抑制剂,具有口服和穿透血脑屏障的优点,脑组织中的药物浓度与血浆浓度的比值(脑/血浆比)达到 1.5,能够减少致癌代谢物 d-2-羟基戊二酸(2-HG) 的积累,用于研究mIDH胶质瘤。
规格 | 价格 | 库存 | 数量 |
---|---|---|---|
1 mg | ¥ 1,980 | 现货 | |
5 mg | ¥ 4,920 | 现货 | |
10 mg | ¥ 7,130 | 现货 | |
25 mg | ¥ 10,600 | 现货 | |
50 mg | ¥ 13,800 | 现货 | |
100 mg | ¥ 17,500 | 现货 |
产品描述 | AGI-026 (AGI-12026) is a novel and potent dual inhibitor of the mutant isocitrate dehydrogenase mIDH1/2 with the advantages of oral administration and penetration of the blood-brain barrier, with a drug concentration to plasma concentration ratio (brain/plasma ratio) of 1.5 in brain tissue, and the ability to reduce the accumulation of the carcinogenic metabolite d-2-hydroxyglutarate (2-HG), which is used in the study of mIDH gliomas. |
别名 | AGI-12026, AGI12026, AGI026, AGI 026 |
分子量 | 443.35 |
分子式 | C18H15F6N7 |
CAS No. | 1446501-77-4 |
Smiles | FC(F)(F)C1=NC(=CC=C1)C=2N=C(N=C(N2)NC(C)C)NC=3C=CN=C(C3)C(F)(F)F |
密度 | 1.31g/cm3 |
存储 | store at low temperature | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
评论内容